Advancements in C isotope tracking of synergistic substrate co-utilization in Pseudomonas species and implications for biotechnology applications.

Curr Opin Biotechnol

Department of Biological and Environmental Engineering, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY 14853, USA; Department of Civil and Environmental Engineering, McCormick School of Engineering and Applied Science, Northwestern University, Evanston, IL 60208, USA. Electronic address:

Published: August 2020

Pseudomonads are well-known to thrive in diverse and complex nutritional habitats, and these capabilities make Pseudomonas species attractive as whole-cell biocatalysts. Industrial bioconversion processes often rely on complex uptake and synergistic metabolic systems due to the presence of varied carbon substrates in nutrient feedstocks. Isotope labeling experiments (ILEs) are emerging techniques used to elucidate cell metabolism following feeding on isotopically enriched substrates and are pivotal to the understanding of carbon partitioning during co-utilization. In this review, we highlight the applications of ILEs to decipher the metabolic networks in Pseudomonas species and evaluate their relevance in optimizing biocatalytic platforms.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.copbio.2020.02.004DOI Listing

Publication Analysis

Top Keywords

pseudomonas species
12
advancements isotope
4
isotope tracking
4
tracking synergistic
4
synergistic substrate
4
substrate co-utilization
4
co-utilization pseudomonas
4
species implications
4
implications biotechnology
4
biotechnology applications
4

Similar Publications

Background: Pseudomonas aeruginosa is a significant opportunistic pathogen, especially in hospital-acquired infections, with plasmid-mediated fluoroquinolone resistance posing a major healthcare threat. This research aimed to isolate fluoroquinolone-resistant P. aeruginosa from patients at Aleppo University Hospital, assess the prevalence of fluoroquinolone resistance, confirm molecular identity, identify plasmid-associated resistance genes, and investigate virulence factors.

View Article and Find Full Text PDF

Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients.

Front Cell Infect Microbiol

January 2025

Center for Infectious Diseases Research (CIDR) and WHO Collaborating Center for Reference and Research on Bacterial Pathogens, American University of Beirut, Beirut, Lebanon.

Introduction: Multidrug resistant Gram-negative bacterial infections are considered a major public health threat. Immunocompromised pediatric patients are at a great risk of severe or overwhelming infections. The aim of this study was to describe the frequency of infections with multidrug resistant (MDR) Gram-negative bacteria (GNB) in immunocompromised pediatric patients and to determine the risk factors.

View Article and Find Full Text PDF

Introduction: Nanobubble ozone stored in hyaluronic acid-decorated liposomes (patent application PCT/TR2022/050177) was used, and the Minimum Inhibitory Concentration (MIC) was found to be 1562 ppm. (patient isolate), (patient isolate), (MRSA) (ATCC12493), and (ATCC25922) bacteria, which are hospital-acquired and healthcare-associated infections, were used. A time-dependent efficacy study was conducted at 1600 ppm.

View Article and Find Full Text PDF

The Role of Nasal Microbiota and Sensitivity in Patients With Chronic Rhinosinusitis at a Rural Tertiary Care Hospital.

Cureus

December 2024

Department of Otolaryngology, Head and Neck Surgery, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, IND.

Background and aim Etiopathogeneses of chronic rhinosinusitis are poorly understood. Recent research emphasizes culture-independent molecular sequencing to identify clusters of flora that may function as drivers of inflammation. Studies also indicate that macrolides are as effective as corticosteroids in controlling chronic rhinosinusitis.

View Article and Find Full Text PDF

Bronchiectasis is a well-recognized chronic respiratory disease characterized by a productive cough and multi-microbial activation syndrome (MMAS) of various respiratory infections due to what can be the permanent dilatation of the bronchi. Bronchiectasis represents an ongoing challenge to conventional antibiotic treatment as the damaged bronchial environment remains conducive to ongoing opportunistic infections and microbial mutations, leading to multi-drug resistance. Standard treatment guidelines are designed to promptly identify and address the primary infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!